Shots:

• Sanofi reveals its focus on its key growth drivers including Dupixent (dupilumab)- vaccines and its pipeline consisting of six potentially transformative therapies. The company is expecting Dupixent to generate ~$11B in its annual sales
• Sanofi also reveals its six investigational therapies which include Fitusiran- BIVV001- Venglustat- SERD (‘859)- Nirsevimab- BTKi (‘168) and plan its R&D day in 2020 to provide a detailed review of its R&D portfolio. Sanofi has decided to terminate further research in diabetes & will not pursue plans to launch efpeglenatide
• Sanofi expects to expand its BOI margin to 30% by 2022 with an aim to exceed it to 32% by 2025. It also plans to separate its OTC business and cut $2.21B in operating costs by 2022. Sanofi will shift its focus to specialty care (immunology- rare diseases- rare blood disorders- neurology and oncology)- vaccines and general medicines

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance